Page 1

prothena Prothena Reports Third Quarter 2021 Financial Results and Business Highlights November 4 , 2021 • Net cash provided by operating and investing activities was $ 111.9 million in the third quarter and $ 114.8 million for the first nine months of 2021 ; Quarter - end cash and restricted cash position was $ 601.5 million • Received $ 140 million from partner payments in third quarter from Novo Nordisk and Bristol Myers Squibb • Announced two key executive appointments to support transition to a fully integrated biotechnology company DUBLIN , Ireland , Nov. 04 , 2021 ( GLOBE NEWSWIRE ) -- Prothena Corporation plc ( NASDAQ : PRTA ) , a late - stage clinical company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise , today reported financial results for the third quarter and first nine months of 2021. In addition , the Company provided business highlights and updated 2021 financial guidance . " Prothena made significant progress across our portfolio in the third quarter . We presented scientific findings highlighting two of our potentially best - in - class Alzheimer's disease programs and advanced our ongoing confirmatory Phase 3 trial of birtamimab in Mayo Stage IV patients with AL amyloidosis . Additionally , we announced the acquisition of our ATTR amyloidosis program by Novo Nordisk and executed the U.S. license agreement for our anti - tau targeting clinical candidate , PRX005 , with Bristol Myers Squibb . Our strategic collaborations have continued to deliver value , contributing $ 140 million in partner payments this quarter , " said Gene Kinney , Ph.D. , President and Chief Executive Officer of Prothena . " As we look ahead , we will continue to focus on driving meaningful growth across our broad portfolio to deliver transformational treatments for patients . " Third Quarter and Recent Business Highlights : Birtamimab , a potential best - in - class amyloid depleter treatment for AL amyloidosis , is an investigational humanized monoclonal antibody designed to directly neutralize soluble toxic aggregates and promote clearance of amyloid that causes organ dysfunction and failure • Confirmatory Phase 3 AFFIRM - AL study of birtamimab in Mayo Stage IV patients with AL amyloidosis is ongoing ( NCT # 04973137 ) PRX004 , a potential first - in - class treatment for ATTR amyloidosis , is a humanized monoclonal antibody designed to deplete the pathogenic , non - native forms of the TTR protein , and is being developed by Novo Nordisk for the treatment of ATTR cardiomyopathy • Announced Novo Nordisk acquisition of ATTR amyloidosis business ; Prothena is eligible to receive a total aggregate of up to $ 1.23 billion • Received $ 60 million upfront payment from Novo Nordisk to date PRX005 , a potential best - in - class treatment for Alzheimer's disease ( AD ) , is an investigational antibody that specifically targets a key epitope within the microtubule binding region ( MTBR ) of tau , a protein implicated in diseases including AD , frontotemporal dementia ( FTD ) , progressive supranuclear palsy ( PSP ) , chronic traumatic encephalopathy ( CTE ) , and other tauopathies . PRX005 is part of the global neuroscience research and development collaboration with Bristol Myers Squibb • Received $ 80 million option payment from Bristol Myers Squibb for execution of U.S. license agreement PRX012 , a potential best - in - class treatment for AD , is an investigational high - potency monoclonal antibody targeting a key epitope at the N - terminus of amyloid beta ( AB ) • Presented preclinical results at the Alzheimer's Association International Conference® 2021 ( AAICⓇ ) demonstrating that PRX012 significantly cleared both pyroglutamate - modified and -unmodified AB plaque in post - mortem brain tissue of late - stage AD patients Dual Aß - tau vaccine , a potential first - in - class prevention and treatment for AD , is a dual - target vaccine targeting key epitopes within the Aß and tau proteins to promote amyloid clearance and blockade of pathogenic tau • AAIC presentation showcased preclinical data demonstrating that Prothena's dual Aß - tau vaccine generated appropriate and balanced antibody titers promoting both phagocytosis of AB plaque and blockade of tau transmission in vitro Corporate • In October , the Company announced two executive appointments to support its transition to a fully integrated biotechnology company . Chief Financial Officer Tran Nguyen was appointed to the additional and newly created role of Chief Strategy Officer and Brandon Smith was appointed the role of Chief Operating Officer . Key Upcoming Milestones :